Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam
- 1 June 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 23 (3), 225-234
- https://doi.org/10.1007/s10637-005-6730-3
Abstract
Indisulam (N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide, GOAL, E7070) is a novel anti-cancer drug currently in phase II clinical development for the treatment of solid tumors. Phase I dose-escalation studies were conducted comparing four treatment schedules. Neutropenia and thrombocytopenia were dose limiting in all schedules. The aim of this study was to describe the extent and the time course of the hematological toxicity and its possible schedule dependency using a semi-physiological model. Data from 142 patients were analyzed using NONMEM. The semi-physiological model comprised a progenitor blood cell compartment, linked to the central circulation compartment, through 3 transition compartments representing the maturation chain in the bone marrow. Plasma concentrations of the drug were assumed to reduce the proliferation rate in the progenitor compartment according to a linear function. A feedback mechanism was included in the model representing the rebound effect of endogenous growth factors. The model was validated using a posterior predictive check. The model adequately described the extent and time course of neutropenia and thrombocytopenia. The mean transition time (MTT, i.e. maturation time in bone marrow) of neutrophils was increased by 47% in patients who received indisulam as a weekly dose administered for four out of every six weeks. For platelets, MTT was increased by 33% in patients who received this schedule and also in patients who received a continuous 120-h infusion. The validation procedure indicated that the model adequately predicts the nadir value of neutrophils and platelets and the time to reach this nadir. A semi-physiological model was successfully applied to describe the time course and extent of the neutropenia and thrombocytopenia after indisulam administration for four treatment schedules.Keywords
This publication has 24 references indexed in Scilit:
- Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.2003
- Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)European Journal Of Cancer, 2003
- Quantitative Chemical Proteomics for Identifying Candidate Drug TargetsAnalytical Chemistry, 2003
- Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across DrugsJournal of Clinical Oncology, 2002
- Population Pharmacokinetics of the Novel Anticancer Agent E7070 During Four Phase I Studies: Model Building and ValidationJournal of Clinical Oncology, 2002
- Population pharmacokinetics and pharmacokinetic‐pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studiesBritish Journal of Clinical Pharmacology, 2002
- Indirect-response model for the time course of leukopenia with anticancer drugs*Clinical Pharmacology & Therapeutics, 1998
- Statistical Graphics in Pharmacokinetics and Pharmacodynamics: A TutorialAnnals of Pharmacotherapy, 1998
- Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEMComputer Methods and Programs in Biomedicine, 1998
- A population model for the leukopenic effect of etoposide*Clinical Pharmacology & Therapeutics, 1995